The most clinically validated liquid biopsy just got
10x bigger with exceptional sensitivity.1,2
Coverage of 739 genes
with the lowest reportable range
down to 0.001% MAF1
Important note: Guardant360 was developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA.
Product availability may vary depending on region.
Accurately quantify disease burden with methylation-based
tumor fraction3,4
Infinity powered
epogenomics & genomics
MAF, mutant allele fraction.
*Average turnaround time from sample receipt to results.
Fast results
in <10 days*